Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness

This observational study is collecting real-world data on how treprostinil (a drug used to treat high blood pressure in the lungs) is used in newborns with pulmonary hypertension — a serious condition where blood pressure in the lung vessels is dangerously high. **You may be eligible if...** - Your baby received at least one dose of IV or subcutaneous treprostinil in clinical practice within the past 5 years - Your baby was up to 44 weeks gestational age (counting from conception) when treprostinil was started - Your baby had pulmonary hypertension or suspected pulmonary hypertension at the time of treatment - Your baby is enrolled in French social security - Parent(s) or legal guardian(s) have provided consent **You may NOT be eligible if...** - There are no exclusion criteria listed for this study — all eligible newborns may be considered Talk to your doctor to see if this trial is right for you.